S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

JNJ Johnson and Johnson

153.14

0.02 (0.01%)

Last Updated: 11:05:43

Delayed by 15 minutes

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities

null

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Johnson and Johnson Charts.

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Johnson and Johnson Charts.

Johnson and Johnson News

Form 144 - Report of proposed sale of securities
Friday 7 February 2025 (3 days ago) • Edgar (US Regulatory)

Johnson & Johnson to Participate in the 45th Annual TD Cowen Healthcare Conference
Monday 3 February 2025 (7 days ago) • Business Wire

Johnson & Johnson soutient le premier document de consensus canadien qui identifie les écarts critiques dans les soins contre le psoriasis pour les patients de couleur
Thursday 23 January 2025 (3 weeks ago) • PR Newswire (Canada)

Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology
Thursday 23 January 2025 (3 weeks ago) • PR Newswire (US)

Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material
Wednesday 22 January 2025 (3 weeks ago) • Edgar (US Regulatory)

Form 8-K/A - Current report: [Amend]
Wednesday 22 January 2025 (3 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 22 January 2025 (3 weeks ago) • Edgar (US Regulatory)

Johnson & Johnson Reports Q4 and Full-Year 2024 Results
Wednesday 22 January 2025 (3 weeks ago) • Business Wire

SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
Tuesday 21 January 2025 (3 weeks ago) • PR Newswire (US)

U.S. Stocks Move Sharply Higher, Dow Reaches One-Month Closing High
Friday 17 January 2025 (3 weeks ago) • IH Market News

RYBREVANT® associé à une chimiothérapie approuvé au Canada comme premier et seul traitement ciblé visant à réduire de plus de la moitié le risque de progression de la maladie ou de décès pour le traitement de deuxième intention des patients att
Thursday 16 January 2025 (4 weeks ago) • PR Newswire (Canada)

RYBREVANT® plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer
Thursday 16 January 2025 (4 weeks ago) • PR Newswire (Canada)

More Johnson and Johnson News Articles

VanEck Morningstar US ES...

BNP Paribas Issuance

Solactive leveraged shor...

BNP Paribas Issuance

Societe Generale Effekten

Vontobel Financial Produ...

Exchange Trading Funds

BNP Paribas Issuance

NLBNPIT1XD91 20991231 10...

NLBNPIT21B73 20991231 40...

Vontobel Financial Produ...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions